Published in Mol Cell on March 01, 2001
Stat proteins and oncogenesis. J Clin Invest (2002) 4.79
Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity (2009) 3.51
Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci (2009) 3.27
STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc Natl Acad Sci U S A (2005) 2.32
Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 2.03
Systematic discovery and characterization of regulatory motifs in ENCODE TF binding experiments. Nucleic Acids Res (2013) 1.96
Role of Stat3 in regulating p53 expression and function. Mol Cell Biol (2005) 1.91
STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci U S A (2005) 1.80
Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol (2008) 1.79
Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling? Cell Div (2010) 1.70
Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest (2003) 1.69
P38 alpha mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli. Mol Biol Cell (2003) 1.65
RACK1 mediates activation of JNK by protein kinase C [corrected]. Mol Cell (2005) 1.59
Down-regulation of NF-kappaB target genes by the AP-1 and STAT complex during the innate immune response in Drosophila. PLoS Biol (2007) 1.47
Regulation of Stat3 nuclear export. J Clin Invest (2003) 1.46
Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity. Proc Natl Acad Sci U S A (2004) 1.46
The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis. Proc Natl Acad Sci U S A (2002) 1.43
An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. J Clin Invest (2002) 1.35
STAT3 Target Genes Relevant to Human Cancers. Cancers (Basel) (2014) 1.29
Leptin-STAT3-G9a Signaling Promotes Obesity-Mediated Breast Cancer Progression. Cancer Res (2015) 1.21
FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol Cell Biol (2003) 1.20
Understanding signaling cascades in melanoma. Photochem Photobiol (2007) 1.10
Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors. J Virol (2009) 1.10
Transcriptional regulation by a DNA-associated form of cyclin D1. Mol Biol Cell (2005) 1.06
Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway. J Biol Chem (2004) 1.06
MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis. Br J Cancer (2013) 1.05
Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein. J Virol (2008) 1.03
Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis. J Biol Chem (2005) 1.02
A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia. Biochem J (2005) 1.02
Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts. Mol Cancer Ther (2010) 1.02
Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression. Exp Cell Res (2006) 0.94
Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells. Cancer Res (2009) 0.94
Prevention of hypovolemic circulatory collapse by IL-6 activated Stat3. PLoS One (2008) 0.93
Complex interactions of transcription factors in mediating cytokine biology in T cells. Immunol Rev (2014) 0.93
STAT3 in Cancer-Friend or Foe? Cancers (Basel) (2014) 0.93
The STATs in cell stress-type responses. Cell Commun Signal (2004) 0.92
Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis. Cytokine Growth Factor Rev (2012) 0.92
Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects. Onco Targets Ther (2012) 0.90
Requirements for PKC-augmented JNK activation by MKK4/7. Int J Biochem Cell Biol (2007) 0.88
Cytokine-induced tumor suppressors: a GRIM story. Cytokine (2010) 0.88
High cell surface death receptor expression determines type I versus type II signaling. J Biol Chem (2011) 0.88
Dual treatment with COX-2 inhibitor and sodium arsenite leads to induction of surface Fas Ligand expression and Fas-Ligand-mediated apoptosis in human melanoma cells. Exp Cell Res (2006) 0.87
Radiation response and regulation of apoptosis induced by a combination of TRAIL and CHX in cells lacking mitochondrial DNA: a role for NF-κB-STAT3-directed gene expression. Exp Cell Res (2011) 0.85
Vaccinia virus B1R kinase interacts with JIP1 and modulates c-Jun-dependent signaling. J Virol (2006) 0.84
Transcriptional activity of c-Jun is critical for the suppression of AR function. Mol Cell Endocrinol (2013) 0.84
Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosis. J Cell Biochem (2011) 0.83
Cord blood stem cells inhibit epidermal growth factor receptor translocation to mitochondria in glioblastoma. PLoS One (2012) 0.82
Small molecule inhibitors targeting activator protein 1 (AP-1). J Med Chem (2014) 0.81
Identification of a structural motif in the tumor-suppressive protein GRIM-19 required for its antitumor activity. Am J Pathol (2010) 0.81
Tumor immunotherapy: lessons from autoimmunity. Front Immunol (2014) 0.80
Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis. J Exp Clin Cancer Res (2016) 0.79
Prediction of oncogenic interactions and cancer-related signaling networks based on network topology. PLoS One (2013) 0.79
The co-repressor SMRT delays DNA damage-induced caspase activation by repressing pro-apoptotic genes and modulating the dynamics of checkpoint kinase 2 activation. PLoS One (2013) 0.79
Identification and characterization of GRIM-1, a cell-death-associated gene product. J Cell Sci (2010) 0.79
Monoclonal Antibodies Specific for STAT3β Reveal Its Contribution to Constitutive STAT3 Phosphorylation in Breast Cancer. Cancers (Basel) (2014) 0.78
STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo. Transl Oncol (2011) 0.78
ALDH1A1 induces resistance to CHOP in diffuse large B-cell lymphoma through activation of the JAK2/STAT3 pathway. Onco Targets Ther (2016) 0.77
Role of STAT3 in lung cancer. JAKSTAT (2015) 0.77
Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms. Clin Exp Med (2016) 0.76
FAS Death Receptor: A Breast Cancer Subtype-Specific Radiation Response Biomarker and Potential Therapeutic Target. Radiat Res (2015) 0.75
Mammary gland selective excision of c-jun identifies its role in mRNA splicing. Cancer Res (2011) 0.75
Immunohistological analysis of the jun family and the signal transducers and activators of transcription in thymus. Anat Res Int (2015) 0.75
Role of microRNAs in inflammation-associated liver cancer. Cancer Biol Med (2016) 0.75
HP1a/KDM4A is involved in the autoregulatory loop of the oncogene gene c-Jun. Epigenetics (2015) 0.75
αNAC inhibition of the FADD-JNK axis plays anti-apoptotic role in multiple cancer cells. Cell Death Dis (2014) 0.75
Idiopathic neutropenia of childhood is associated with Fas/FasL expression. Clin Immunol (2008) 0.75
FAS-based cell depletion facilitates the selective isolation of mouse induced pluripotent stem cells. PLoS One (2014) 0.75
Prediction of coronary heart disease using risk factor categories. Circulation (1998) 48.81
Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation (1998) 19.93
Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA (1994) 11.63
Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med (2001) 10.54
Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation (1993) 9.24
The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol (1993) 8.01
Lifetime risk of developing coronary heart disease. Lancet (1999) 7.54
Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation (1997) 7.34
Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol (1998) 6.76
Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med (1999) 6.72
Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J Virol (2000) 6.22
Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation (1996) 6.20
Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA (2000) 6.00
Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell (1994) 5.79
Accuracy of death certificates for coding coronary heart disease as the cause of death. Ann Intern Med (1998) 5.63
Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet (2001) 5.54
Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol (1999) 5.43
Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation (2001) 5.11
Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. Circulation (1999) 5.04
Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med (1999) 5.01
Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet (1996) 4.84
Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation (2000) 4.63
Interferon-induced transcription of a gene encoding a 15-kDa protein depends on an upstream enhancer element. Proc Natl Acad Sci U S A (1987) 4.61
Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation (1994) 4.52
Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol (1998) 4.44
The somatic replication of DNA methylation. Cell (1981) 4.42
Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science (1997) 4.37
Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol (1998) 4.09
Risk factors for incident radiographic knee osteoarthritis in the elderly: the Framingham Study. Arthritis Rheum (1997) 4.08
ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev (2001) 4.06
Regulation of JNK signaling by GSTp. EMBO J (1999) 4.06
Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA (1987) 4.05
Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation (1995) 4.04
Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med (1997) 3.96
The incidence and natural history of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum (1995) 3.93
Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation (1998) 3.89
Cancer: improving early detection and prevention. A community practice randomised trial. BMJ (1992) 3.76
An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study) Am J Cardiol (1992) 3.66
Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci U S A (1996) 3.62
Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of I kappa B alpha. Mol Cell (1999) 3.58
Effects of ambient air pollution on nonelderly asthma hospital admissions in Seattle, Washington, 1987-1994. Epidemiology (1999) 3.57
Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging Cell (2006) 3.44
Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation (1994) 3.44
Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling. Proc Natl Acad Sci U S A (1996) 3.26
Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol (1995) 3.19
Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol (1995) 3.08
Impaired heart rate response to graded exercise. Prognostic implications of chronotropic incompetence in the Framingham Heart Study. Circulation (1996) 3.07
Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int (1999) 2.95
Interferon-stimulated transcription: isolation of an inducible gene and identification of its regulatory region. Proc Natl Acad Sci U S A (1986) 2.92
DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J Biol Chem (2000) 2.90
Reduced heart rate variability and new-onset hypertension: insights into pathogenesis of hypertension: the Framingham Heart Study. Hypertension (1998) 2.86
The V protein of human parainfluenza virus 2 antagonizes type I interferon responses by destabilizing signal transducer and activator of transcription 2. Virology (2001) 2.83
Profile for estimating risk of heart failure. Arch Intern Med (1999) 2.81
Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med (1997) 2.81
Mitral annular calcification and the risk of stroke in an elderly cohort. N Engl J Med (1992) 2.77
Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension (2000) 2.76
TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem (2001) 2.65
Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol (1987) 2.60
ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol (1999) 2.58
Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol (2001) 2.57
Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation (2001) 2.54
Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med (1999) 2.53
Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) Am J Cardiol (1999) 2.51
Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. N Engl J Med (1996) 2.49
Secular trends in the prevalence of atrial fibrillation: The Framingham Study. Am Heart J (1996) 2.47
Reconstitution of membrane proteins into liposomes: application to energy-transducing membrane proteins. Biochim Biophys Acta (1995) 2.47
Evidence for a Mendelian gene in a segregation analysis of generalized radiographic osteoarthritis: the Framingham Study. Arthritis Rheum (1998) 2.45
The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA (1991) 2.44
Role of redox potential and reactive oxygen species in stress signaling. Oncogene (1999) 2.37
JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev (1998) 2.29
Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). Am J Cardiol (2000) 2.28
MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci U S A (1998) 2.27
Prognosis after the onset of coronary heart disease. An investigation of differences in outcome between the sexes according to initial coronary disease presentation. Circulation (1993) 2.27
Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet (2003) 2.26
Resurgence of sleeping sickness in Tambura County, Sudan. Am J Trop Med Hyg (1999) 2.24
Prognosis after first myocardial infarction. Comparison of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart Study. JAMA (1992) 2.22
Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol (1991) 2.19
Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis (2004) 2.17
Natural history of progressive ischemic stroke in a population treated with heparin. Stroke (1990) 2.14
Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. J Biol Chem (2001) 2.14
Distribution and categorization of echocardiographic measurements in relation to reference limits: the Framingham Heart Study: formulation of a height- and sex-specific classification and its prospective validation. Circulation (1997) 2.14
ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat Cell Biol (2001) 2.14
Retracted SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell (2000) 2.12
The association of chronic cough with the risk of myocardial infarction: the Framingham Heart Study. Am J Med (1999) 2.09
Prognostic implications of asymptomatic ventricular arrhythmias: the Framingham Heart Study. Ann Intern Med (1992) 2.08
Risk of infection and death among post-splenectomy patients. J Infect (2001) 2.06
HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IkappaB and beta-catenin. Oncogene (1999) 2.05
Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study. JAMA (1994) 2.03
Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor. Mol Cell (2000) 2.02
Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol (1987) 2.01
Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase. Oncogene (1996) 2.00
Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity. EMBO J (1995) 2.00
Myalgia, fever, abnormal muscle enzymes and blue urine in a farmworker from Thailand. Isr Med Assoc J (2001) 1.99
Death rates from coronary disease--progress and a puzzling paradox. N Engl J Med (1998) 1.95
Mdm2 association with p53 targets its ubiquitination. Oncogene (1998) 1.94
Bone mineral density and risk of incident and progressive radiographic knee osteoarthritis in women: the Framingham Study. J Rheumatol (2000) 1.94
FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev (1999) 1.94
Influence of contemporary versus 30-year blood pressure levels on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol (1991) 1.91
Transcription of interferon-stimulated genes is induced by adenovirus particles but is suppressed by E1A gene products. J Virol (1988) 1.88